Innoviva Company Profile (NASDAQ:INVA)

About Innoviva (NASDAQ:INVA)

Innoviva logoInnoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:INVA
  • CUSIP: 88338T10
  • Web:
  • Market Cap: $1.51682 billion
  • Outstanding Shares: 109,361,000
Average Prices:
  • 50 Day Moving Avg: $13.18
  • 200 Day Moving Avg: $12.81
  • 52 Week Range: $8.67 - $14.55
  • Trailing P/E Ratio: 17.37
  • Foreward P/E Ratio: 7.80
  • P/E Growth: 0.28
Sales & Book Value:
  • Annual Revenue: $175.98 million
  • Price / Sales: 8.58
  • Book Value: ($2.71) per share
  • Price / Book: -5.10
  • EBIDTA: $142.91 million
  • Net Margins: 52.56%
  • Return on Equity: -27.37%
  • Return on Assets: 24.45%
  • Debt-to-Equity Ratio: -2.15%
  • Current Ratio: 7.31%
  • Quick Ratio: 7.31%
  • Average Volume: 952,512 shs.
  • Beta: 2.58
  • Short Ratio: 16.67

Frequently Asked Questions for Innoviva (NASDAQ:INVA)

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) issued its earnings results on Wednesday, July, 26th. The company reported $0.30 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.28 by $0.02. The business earned $58.60 million during the quarter, compared to analyst estimates of $50.53 million. Innoviva had a negative return on equity of 27.37% and a net margin of 52.56%. Innoviva's revenue was up 80.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.13 EPS. View Innoviva's Earnings History.

Where is Innoviva's stock going? Where will Innoviva's stock price be in 2017?

3 equities research analysts have issued 1 year price targets for Innoviva's stock. Their predictions range from $13.00 to $16.00. On average, they anticipate Innoviva's stock price to reach $14.67 in the next twelve months. View Analyst Ratings for Innoviva.

Who are some of Innoviva's key competitors?

Who are Innoviva's key executives?

Innoviva's management team includes the folowing people:

  • William H. Waltrip, Independent Chairman of the Board
  • Eric D'Esparbes, Chief Financial Officer, Senior Vice President
  • Theodore J. Witek Jr., Senior Vice President, Chief Scientific Officer
  • Michael E. Faerm, Senior Vice President and Chief Business Officer
  • Michael W. Aguiar, President, Chief Executive Officer, Director
  • Barbara G. Duncan, Independent Director
  • Catherine J. Friedman, Independent Director
  • Patrick G. LePore, Independent Director
  • Paul A. Pepe, Independent Director

Who owns Innoviva stock?

Innoviva's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.88%), BlackRock Inc. (11.12%), Vanguard Group Inc. (6.93%), State Street Corp (2.48%), First Eagle Investment Management LLC (2.49%) and Wells Fargo & Company MN (1.86%). Company insiders that own Innoviva stock include Eric Desparbes, James L Tyree, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.

Who sold Innoviva stock? Who is selling Innoviva stock?

Innoviva's stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, Empyrean Capital Partners LP, Icon Advisers Inc. Co., Wells Fargo & Company MN, Old Mutual Global Investors UK Ltd., OxFORD Asset Management LLP, State of New Jersey Common Pension Fund D and JPMorgan Chase & Co.. Company insiders that have sold Innoviva stock in the last year include Eric Desparbes, Theodore J Jr Witek and Theodore L Witek Jr. View Insider Buying and Selling for Innoviva.

Who bought Innoviva stock? Who is buying Innoviva stock?

Innoviva's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Dimensional Fund Advisors LP, Gotham Asset Management LLC, PDT Partners LLC, Acadian Asset Management LLC, State Street Corp and Spark Investment Management LLC. View Insider Buying and Selling for Innoviva.

How do I buy Innoviva stock?

Shares of Innoviva can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innoviva's stock price today?

One share of Innoviva stock can currently be purchased for approximately $13.81.

MarketBeat Community Rating for Innoviva (NASDAQ INVA)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  287
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Innoviva (NASDAQ:INVA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $14.67 (6.20% upside)

Analysts' Ratings History for Innoviva (NASDAQ:INVA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017Stifel NicolausReiterated RatingHold -> NeutralLowView Rating Details
7/28/2017Cowen and CompanySet Price TargetBuy$16.00MediumView Rating Details
7/27/2017Robert W. BairdReiterated RatingNeutral$11.00 -> $13.00MediumView Rating Details
10/5/2015Morgan StanleyReiterated RatingOverweight$7.00 -> $9.00N/AView Rating Details
(Data available from 9/19/2015 forward)


Earnings History for Innoviva (NASDAQ:INVA)
Earnings by Quarter for Innoviva (NASDAQ:INVA)
Earnings History by Quarter for Innoviva (NASDAQ INVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017Q2 2017$0.28$0.30$50.53 million$58.60 millionViewN/AView Earnings Details
4/27/2017Q1 2017$0.27$0.15$47.66 million$40.50 millionViewN/AView Earnings Details
2/9/2017Q4 2016$0.19$0.22$40.72 million$43.60 millionViewListenView Earnings Details
10/27/2016Q316$0.19$0.16$38.71 million$33.30 millionViewListenView Earnings Details
7/28/2016Q216$0.12$0.17$31.13 million$32.47 millionViewListenView Earnings Details
4/28/2016Q116$0.09$0.04$28.61 million$24.17 millionViewListenView Earnings Details
2/3/2016Q415$0.01$0.04$20.17 million$22.80 millionViewN/AView Earnings Details
10/28/2015Q315($0.03)($0.04)$15.23 million$13.56 millionViewListenView Earnings Details
7/29/2015Q2($0.06)($0.07)$10.90 million$10.70 millionViewListenView Earnings Details
5/6/2015Q115($0.08)($0.09)$8.64 million$6.90 millionViewListenView Earnings Details
2/18/2015Q414($0.14)($0.14)$5.42 million$7.30 millionViewN/AView Earnings Details
10/30/2014Q314($0.15)($0.19)$5.06 million$1.00 millionViewN/AView Earnings Details
8/18/2014($0.53)($0.18)ViewN/AView Earnings Details
8/6/2014Q214($0.53)($0.18)$4.39 million$0.93 millionViewN/AView Earnings Details
5/6/2014Q114($0.53)($0.62)$4.52 million$0.17 millionViewN/AView Earnings Details
2/6/2014Q413($0.38)($0.46)$6.03 million$1.60 millionViewN/AView Earnings Details
10/24/2013Q313$0.69($0.44)$3.08 million$0.44 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.46)($0.37)$1.43 million$1.33 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.38)($0.39)$2.71 million$1.34 millionViewN/AView Earnings Details
2/12/2013Q4 2012($0.36)($0.33)$3.88 million$5.80 millionViewN/AView Earnings Details
10/30/2012($0.39)($0.37)ViewN/AView Earnings Details
7/31/2012($0.42)($0.42)ViewN/AView Earnings Details
4/26/2012$1.02$0.93ViewN/AView Earnings Details
2/9/2012($0.38)($0.45)ViewN/AView Earnings Details
10/27/2011($0.33)($0.37)ViewN/AView Earnings Details
7/28/2011($0.27)($0.31)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Innoviva (NASDAQ:INVA)
Current Year EPS Consensus Estimate: $1.16 EPS
Next Year EPS Consensus Estimate: $1.77 EPS


Dividend History by Quarter for Innoviva (NASDAQ INVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Innoviva (NASDAQ:INVA)
Insider Ownership Percentage: 1.60%
Institutional Ownership Percentage: 69.06%
Insider Trades by Quarter for Innoviva (NASDAQ:INVA)
Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)
Insider Trades by Quarter for Innoviva (NASDAQ:INVA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/21/2017Eric DesparbesCFOSell1,825$12.20$22,265.00View SEC Filing  
5/22/2017Eric DesparbesCFOSell1,825$11.85$21,626.25View SEC Filing  
5/22/2017Theodore J Jr. WitekVPSell7,815$12.01$93,858.15View SEC Filing  
2/21/2017Eric DesparbesCFOSell1,825$12.07$22,027.75View SEC Filing  
11/22/2016Theodore L Witek JrVPSell3,700$10.84$40,108.00View SEC Filing  
11/21/2016Eric DesparbesCFOSell1,800$10.89$19,602.00View SEC Filing  
8/22/2016Eric DesparbesCFOSell3,700$11.77$43,549.00View SEC Filing  
5/18/2016James L TyreeDirectorSell813$10.47$8,512.11View SEC Filing  
5/11/2015Plc GlaxosmithklineMajor ShareholderBuy85,579$1,369,260.00$117,179,901,540.00View SEC Filing  
8/13/2014Junning LeeVPSell53,424$22.50$1,202,040.00View SEC Filing  
8/12/2014Bradford J ShaferSVPSell28,156$22.13$623,092.28View SEC Filing  
8/11/2014Bradford J ShaferSVPSell27,108$22.12$599,628.96View SEC Filing  
9/12/2013Rick WinninghamCEOSell22,353$40.03$894,790.59View SEC Filing  
7/30/2013Mathai MammenSVPSell7,000$36.51$255,570.00View SEC Filing  
6/7/2013Bradford J ShaferSVPSell31,038$35.04$1,087,571.52View SEC Filing  
5/29/2013David L BrinkleyInsiderSell3,808$35.01$133,318.08View SEC Filing  
5/13/2013David L BrinkleyInsiderSell16,129$40.33$650,482.57View SEC Filing  
8/7/2012Michael W AguiarCFOSell60,000$27.04$1,622,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Innoviva (NASDAQ:INVA)
Latest Headlines for Innoviva (NASDAQ:INVA)
DateHeadline logoFinancial Contrast: Opko Health (OPK) versus Innoviva (INVA) - September 19 at 8:52 AM logoGlaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU - September 18 at 7:26 PM logoInnoviva, Inc. (INVA) Given "Neutral" Rating at Stifel Nicolaus - September 16 at 9:40 PM logoInnoviva (INVA) Presents At Baird's 2017 Global Healthcare Conference - Slideshow - September 8 at 11:39 PM logoInnoviva to Participate in Morgan Stanley’s Global Healthcare Unplugged Conference on September 12 - September 7 at 8:13 PM logo$57.42 Million in Sales Expected for Innoviva, Inc. (INVA) This Quarter - September 7 at 5:50 AM logo$0.32 Earnings Per Share Expected for Innoviva, Inc. (INVA) This Quarter - September 5 at 10:26 AM logoInnoviva, Inc. (INVA) Downgraded by ValuEngine to Hold - September 3 at 9:02 AM logoInnoviva to Participate in Baird Global Healthcare Conference on September 7 - August 31 at 6:15 AM logoStocks Showing Improving Market Leadership: Innoviva Earns 84 RS Rating - August 30 at 2:25 AM logoInnoviva, Inc. breached its 50 day moving average in a Bullish Manner : INVA-US : August 28, 2017 - August 28 at 7:32 PM logoInnoviva, Inc. – Value Analysis (NASDAQ:INVA) : August 21, 2017 - August 23 at 5:24 AM logoEric Desparbes Sells 1,825 Shares of Innoviva, Inc. (INVA) Stock - August 22 at 8:22 PM logoInnoviva Completes Refinancing of its 9% 2029 Non-Recourse Notes - August 21 at 8:53 AM logo Brokerages Anticipate Innoviva, Inc. (INVA) Will Announce Quarterly Sales of $57.42 Million - August 19 at 1:18 AM logoZacks: Brokerages Expect Innoviva, Inc. (INVA) Will Announce Earnings of $0.31 Per Share - August 17 at 10:24 PM logoInnoviva, Inc. (INVA) Downgraded by Zacks Investment Research to "Hold" - August 16 at 10:56 PM logoTracking Seth Klarman's Baupost Group Holdings - Q2 2017 Update - August 12 at 4:48 AM logoSee what the IHS Markit Score report has to say about Innoviva Inc. - August 9 at 8:12 PM logoInnoviva, Inc. breached its 50 day moving average in a Bearish Manner : INVA-US : August 9, 2017 - August 9 at 8:12 PM logoInnoviva, Inc. Announces Closing of $175 Million Offering of 2.50% Convertible Senior Notes and Exercise of the Initial Purchasers’ $17.5 million Over-Allotment Option - August 7 at 7:23 PM logoIllumina (ILMN) Catches Eye: Stock Soars 14.8% - August 3 at 8:02 PM logoInnoviva, Inc. Prices Offering of $175 Million of 2.50% Convertible Senior Notes - August 1 at 8:31 PM logoInnoviva, Inc. -- Moody's assigns B3 CFR to Innoviva; stable outlook - August 1 at 3:31 PM logo$52.12 Million in Sales Expected for Innoviva, Inc. (INVA) This Quarter - August 1 at 8:05 AM logoETFs with exposure to Innoviva, Inc. : July 31, 2017 - July 31 at 7:18 PM logoInnoviva Announces Proposed Offering of $175 Million of Convertible Senior Notes - July 31 at 7:18 PM logoInnoviva, Inc. (INVA) Expected to Post Earnings of $0.32 Per Share - July 30 at 4:28 PM logoInnoviva, Inc. (NASDAQ:INVA) Earns Neutral Rating from Robert W. Baird - July 27 at 11:00 PM logoEdited Transcript of INVA earnings conference call or presentation 26-Jul-17 9:00pm GMT - July 27 at 10:58 PM logoInnoviva, Inc. (INVA) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS - July 26 at 9:14 PM logoInnoviva Reports Strong Second Quarter 2017 Financial Results - July 26 at 8:13 PM logoInnoviva beats 2Q profit forecasts - July 26 at 8:13 PM logoGSK Submits EU Filing For Extended Use Of Relvar Ellipta - July 21 at 4:13 PM logoGSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an ICS/LABA Combination - July 21 at 4:13 PM logoInnoviva to Report First Quarter Financial Results on July 26 at 5:00 p.m. EDT - July 19 at 10:18 PM logoInnoviva, Inc. (NASDAQ:INVA) Upgraded by Zacks Investment Research to Hold - July 18 at 12:27 AM logoInitiating Research Reports on Application Software Equities -- Sphere 3D ... - July 17 at 8:21 AM logoInitiating Research Reports on Application Software Equities -- Sphere 3D, Cadence Design Systems, Innoviva, and Shopify - July 17 at 8:21 AM logoETFs with exposure to Innoviva, Inc. : July 10, 2017 - July 10 at 7:56 PM logoZacks: Analysts Expect Innoviva, Inc. (NASDAQ:INVA) Will Post Quarterly Sales of $49.12 Million - July 8 at 9:38 AM logoZacks: Analysts Anticipate Innoviva, Inc. (INVA) Will Announce Earnings of $0.28 Per Share - July 6 at 12:19 PM logoInnoviva, Inc. (INVA) Lowered to "Sell" at Zacks Investment Research - July 4 at 12:36 AM logoETFs with exposure to Innoviva, Inc. : June 20, 2017 - June 20 at 6:52 PM logoInnoviva, Inc. :INVA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017 - June 19 at 12:19 PM logoInnoviva, Inc. (INVA) Expected to Announce Quarterly Sales of $49.12 Million - June 14 at 11:50 AM logoZacks: Brokerages Anticipate Innoviva, Inc. (INVA) to Post $0.28 Earnings Per Share - June 12 at 2:32 PM logoInnoviva Inc (INVA) Sees Significant Decline in Short Interest - June 9 at 3:50 PM logoValuEngine Downgrades Innoviva Inc (INVA) to Hold - June 4 at 10:38 AM logoCan This Biotech Stock With 645% EPS Growth Launch New Breakout? - June 2 at 7:20 PM



Innoviva (INVA) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by Staff